Compare PBT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | IVA |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.1M | 769.0M |
| IPO Year | N/A | 2020 |
| Metric | PBT | IVA |
|---|---|---|
| Price | $17.26 | $4.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.14 |
| AVG Volume (30 Days) | 87.7K | ★ 182.3K |
| Earning Date | 01-01-0001 | 09-29-2025 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | $17,266,423.00 | ★ $19,929,536.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.01 | $2.11 |
| 52 Week High | $20.46 | $7.98 |
| Indicator | PBT | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 52.12 |
| Support Level | $17.13 | $4.05 |
| Resistance Level | $18.73 | $4.61 |
| Average True Range (ATR) | 0.77 | 0.20 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 9.39 | 73.85 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.